Patterns and preferences of antidiabetic drug use in Turkish patients with type 2 diabetes – A nationwide cross-sectional study (TEMD treatment study)

• Published in: Diabetes research and clinical practice Vol. 171; p. 108556
• Main Authors: Haymana, Cem, Sonmez, Alper, Demirci, Ibrahim, Fidan Yaylalı, Guzin, Nuhoglu, Irfan, Sancak, Seda, Yilmaz, Murat, Altuntas, Yuksel, Dinccag, Nevin, Sabuncu, Tevfik, Bayram, Fahri, Satman, Ilhan
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.01.2021
• Subjects: Complex treatment regimens; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - drug therapy; Diabetic complications; Female; Humans; Hypoglycemic Agents - therapeutic use; Insulin; Male; Middle Aged; Oral antidiabetics; Turkey; Type 2 diabetes; Turkey; Type 2 diabetes; Diabetic complications; Insulin; Complex treatment regimens; Oral antidiabetics
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2020.108556

The treatment preferences in type 2 diabetes (T2DM) are affected by multiple factors. This survey aims to find out the profiles of the utilization of antidiabetics and their determinants. The nationwide, multicenter TEMD survey consecutively enrolled patients with T2DM (n = 4678). Medications including oral antidiabetics (OAD) and injectable regimens were recorded. Multiple injectable regimens with or without OADs were defined as complex treatments. A total of 4678 patients with T2DM (mean age: 58.5 ± 10.4 years, 59% female) were enrolled. More than half of patients (n = 2372; 50.7%) were using injectable regimens with or without OADs, and others (n = 2306, 49.3%) were using only OADs. The most common OADs were metformin (93.5%), secretagogues (40.1%), and DPP-4 inhibitors (37.2%). The rates of the use of basal, basal-bolus and premix insulin were 26.5%, 39.5% and 22.4%, respectively. Patients using OADs achieved better glycemia, blood pressure and weight control (p < 0.001 for all) but poorer LDL-C control (p < 0.001). The independent associates of complex treatments were diabetes duration, obesity, eGFR, glycated haemoglobin, macro and microvascular complications, education level, and self-reported hypoglycemia. This study is the first nationwide report to show that almost half of the patients with T2DM are using injectable regimens in Turkey.